INVESTOR RELATIONS

Media Coverage

Media

Episode 24 – Genetic engineering for allogeneic immunotherapy
October 24, 2023
Episode 24 – Genetic engineering for allogeneic immunotherapy
Drug Target Review
The impact of cell therapies on cancer treatments
October 13, 2023
The impact of cell therapies on cancer treatments
PMLiVE
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies
September 06, 2023
Eterna Therapeutics Teams with Lineage Cell on Transplant Therapies
Exec Edge
mRNA-engineered iPSC-derived Cell Therapies Hold Potential for Tackling Solid Tumors
August 14, 2023
mRNA-engineered iPSC-derived Cell Therapies Hold Potential for Tackling Solid Tumors
CGTLive
The promise of iPSC-based multi-cell therapeutics
July 05, 2023
The promise of iPSC-based multi-cell therapeutics
Drug Target Review
Tapping the Potential of mRNA in Cellular Reprogramming and Beyond
June 01, 2023
Tapping the Potential of mRNA in Cellular Reprogramming and Beyond
Longevity Technology
Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel
May 24, 2023
Eterna Therapeutics Appoints Megan Yung as CSO, General Counsel
Exec Edge
Kyle Garland, PhD on the Potential of mRNA-engineered iPSC-derived Cell Therapies for Solid Tumors
May 18, 2023
Kyle Garland, PhD on the Potential of mRNA-engineered iPSC-derived Cell Therapies for Solid Tumors
CGTLive
Eterna Acquires Allogeneic Immuno-Oncology Platform from Exacis
May 03, 2023
Eterna Acquires Allogeneic Immuno-Oncology Platform from Exacis
Labiotech
Exclusive: RNA Firm Eterna Therapeutics Buys Neighboring Startup for $50M
May 02, 2023
Exclusive: RNA Firm Eterna Therapeutics Buys Neighboring Startup for $50M
Boston Business Journal

Media Kit

If you’re a media professional, please take advantage of our digital media kit.

Explore More

Media Inquiries

For additional information, please direct your media inquiries to:

EternaPR@westwicke.com